Transforming growth factor-beta in systemic sclerosis (scleroderma)

John Varga*, Michael L. Whitfield

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Deregulated transforming growth factor-beta (TGF-beta) activity and responses play prominent roles in the pathogenesis of systemic sclerosis (SSc), a chronic and progressive connective tissue disease characterized by fibrosis of the skin and internal organs. Systemic sclerosis has highly heterogeneous clinical manifestations, and patients can be classified into multiple subgroups on the basis of distinct molecular signatures defined by transcriptional profiling of gene expression in target organs. Current research to uncover how TGF-beta regulates fibroblast function opens the door for the discovery of targeted therapies. Anti-fibrotic treatments that selectively block TGF-β expression, biological activity or intracellular signaling in SSc are currently under development.

Original languageEnglish (US)
Pages (from-to)226-235
Number of pages10
JournalFrontiers in Bioscience - Scholar
Volume1 S
Issue number1
StatePublished - Jan 6 2009


  • Animal models
  • Dna microarrays
  • Fibrosis
  • Gene expression profiling
  • Review
  • Scleroderma
  • Systemic sclerosis
  • TGF-beta

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Immunology and Microbiology


Dive into the research topics of 'Transforming growth factor-beta in systemic sclerosis (scleroderma)'. Together they form a unique fingerprint.

Cite this